PUBLISHER: Global Market Insights Inc. | PRODUCT CODE: 1833404
PUBLISHER: Global Market Insights Inc. | PRODUCT CODE: 1833404
North America Diabetes Care Devices Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025 - 2034
North America Diabetes Care Devices Market was valued at USD 21 billion in 2024 and is estimated to grow at a CAGR of 12.4% to reach USD 66.8 billion by 2034.
The rising incidence of diabetes, particularly type 2 diabetes, in North America is a major driver for the diabetes care devices market. With over 30 million people living with diabetes in the U.S. alone, the demand for reliable glucose monitors, insulin pumps, and continuous glucose monitoring (CGM) systems is increasing. This growing patient population is fueling the need for more effective and accessible diabetes management tools.
| Market Scope | |
|---|---|
| Start Year | 2024 |
| Forecast Year | 2025-2034 |
| Start Value | $21 billion |
| Forecast Value | $66.8 billion |
| CAGR | 12.4% |
Rising Adoption of Devices
The devices segment held a notable share in 2024, driven by technological advancements. Devices such as continuous glucose monitors (CGMs), insulin pumps, and smart glucose meters have transformed diabetes management by offering real-time monitoring and better control of blood sugar levels. CGMs have become a game-changer for people living with diabetes, providing them with continuous, non-invasive blood glucose tracking.
Homecare to Gain Traction
The home care segment generated significant revenues in 2024. With a growing preference for managing chronic conditions at home, the demand for home-use diabetes devices such as home glucose monitors, insulin pumps, and portable A1c analyzers has surged. The rise of telemedicine and remote patient monitoring is further accelerating this trend, as patients now have more flexibility in managing their diabetes without frequent visits to healthcare facilities.
U.S. to Emerge as a Lucrative Region
U.S. diabetes care devices market is poised to grow significantly through 2034, driven by a combination of high disease prevalence, technological advancements, and a growing focus on chronic disease management. With over 30 million Americans living with diabetes, the market has seen a shift from traditional blood glucose meters to more sophisticated technologies such as CGMs, smart insulin pens, and automated insulin delivery systems.
Major players in the North America diabetes care devices market are Abbott Laboratories, ARKRAY, Ascensia Diabetes Care, B. Braun Melsungen, Becton, Dickinson and Company, BIONIME, DarioHealth, Dexcom, Dr. Reddy's Laboratories, Eli Lilly and Company, F. Hoffmann-La Roche, Insulet, LifeScan Inc., Medtronic, Nova Biomedical, Novo Nordisk, Platinum Equity Advisors, Sanofi, Sinocare, and Tandem Diabetes Care.
To strengthen their foothold in the North America diabetes care devices market, companies are adopting several key strategies. First, manufacturers are heavily investing in research and development (R&D) to innovate and create more accurate, user-friendly, and cost-effective devices. This is especially evident in the push toward personalized diabetes management with products like CGMs that provide real-time data synced to mobile apps. Strategic partnerships are also a critical part of the growth strategy. For example, companies are collaborating with insurance providers, healthcare networks, and technology firms to improve device accessibility and ensure that patients have more affordable options.
Table of Contents
Chapter 1 Methodology and Scope
- 1.1 Market scope and definition
- 1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
- 1.3 Data mining sources
- 1.3.1 Regional/country
- 1.4 Base estimates and calculations
- 1.4.1 Base year calculation
- 1.4.2 Key trends for market estimation
- 1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.6 Forecast model
- 1.7 Research assumptions and limitations
Chapter 2 Executive Summary
- 2.1 Industry 3600 synopsis
- 2.2 Key market trends
- 2.2.1 Regional trends
- 2.2.2 Product trends
- 2.2.3 End use trends
- 2.3 CXO perspectives: Strategic imperatives
- 2.3.1 Key decision points for industry executives
- 2.3.2 Critical success factors for market players
- 2.4 Future outlook and strategic recommendations
Chapter 3 Industry Insights
- 3.1 Industry ecosystem analysis
- 3.1.1 Supplier landscape
- 3.1.2 Value addition at each stage
- 3.1.3 Factor affecting the value chain
- 3.2 Industry impact forces
- 3.2.1 Growth drivers
- 3.2.1.1 Growing prevalence of diabetes
- 3.2.1.2 Rising technological advancements in North America diabetes care devices
- 3.2.1.3 Increased healthcare spending and accessibility
- 3.2.2 Industry pitfalls and challenges
- 3.2.2.1 High cost of diabetes care devices
- 3.2.2.2 Limited reimbursement policies
- 3.2.3 Market opportunities
- 3.2.3.1 Growth of mobile health and digital platforms
- 3.2.1 Growth drivers
- 3.3 Growth potential analysis
- 3.4 Regulatory landscape
- 3.4.1 U.S.
- 3.4.2 Canada
- 3.5 Technological advancements
- 3.5.1 Current technological trends
- 3.5.2 Emerging technologies
- 3.6 Supply chain and distribution analysis
- 3.7 Reimbursement scenario
- 3.8 Pricing analysis, 2024
- 3.9 Future market trends
- 3.10 Gap analysis
- 3.11 Porter's analysis
- 3.12 PESTEL analysis
Chapter 4 Competitive Landscape, 2024
- 4.1 Introduction
- 4.2 Company market share analysis
- 4.2.1 North America
- 4.2.2 U.S.
- 4.3 Company matrix analysis
- 4.4 Competitive analysis of major market players
- 4.5 Competitive positioning matrix
- 4.6 Key developments
- 4.6.1 Mergers and acquisitions
- 4.6.2 Partnerships and collaborations
- 4.6.3 New product launches
- 4.6.4 Expansion plans
Chapter 5 Market Estimates and Forecast, By Product, 2021 - 2034 ($ Mn)
- 5.1 Key trends
- 5.2 Device
- 5.2.1 Blood glucose monitoring devices
- 5.2.1.1 Self-monitoring blood glucose meters
- 5.2.1.2 Continuous glucose monitors
- 5.2.2 Insulin delivery devices
- 5.2.2.1 Insulin pumps
- 5.2.2.1.1 Tubed pumps
- 5.2.2.1.2 Tubeless pumps
- 5.2.2.2 Pens
- 5.2.2.2.1 Reusable
- 5.2.2.2.2 Disposable
- 5.2.2.1 Insulin pumps
- 5.2.3 Other insulin delivery devices
- 5.2.1 Blood glucose monitoring devices
- 5.3 Consumables
- 5.3.1 Testing strips
- 5.3.2 Lancets
- 5.3.3 Pen needles
- 5.3.3.1 Standard
- 5.3.3.2 Safety
- 5.3.4 Syringes
- 5.3.5 Insulin pumps consumables
Chapter 6 Market Estimates and Forecast, By End Use, 2021 - 2034 ($ Mn)
- 6.1 Key trends
- 6.2 Hospital
- 6.3 Ambulatory surgical centres
- 6.4 Diagnostic centres
- 6.5 Homecare
- 6.6 Other end use
Chapter 7 Market Estimates and Forecast, By Country, 2021 - 2034 ($ Mn)
- 7.1 Key trends
- 7.2 U.S.
- 7.3 Canada
Chapter 8 Company Profiles
- 8.1 Abbott Laboratories
- 8.2 ARKRAY
- 8.3 Ascensia Diabetes Care
- 8.4 B. Braun Melsungen
- 8.5 Becton, Dickinson and Company
- 8.6 BIONIME
- 8.7 DarioHealth
- 8.8 Dexcom
- 8.9 Dr. Reddy’s Laboratories
- 8.10 Eli Lilly and Company
- 8.11 F. Hoffmann-La Roche
- 8.12 Insulet
- 8.13 LifeScan Inc
- 8.14 Medtronic
- 8.15 Nova Biomedical
- 8.16 Novo Nordisk
- 8.17 Platinum Equity Advisors
- 8.18 Sanofi
- 8.19 Sinocare
- 8.20 Tandem Diabetes Care
